Clinical genomic testing is becoming routine in prostate cancer, as biomarker‐driven
therapies such as poly‐ADP ribose polymerase (PARP) inhibitors and anti‐PD1 …

The impact of variations in the three-dimensional structure of the genome has been
recognized, but solid cancer tissue studies are limited. Here, we performed integrated deep …

Purpose: Men with metastatic castration-resistant prostate cancer (mCRPC) frequently
develop resistance to androgen receptor signaling inhibitor (ARSI) treatment; therefore, new …

Our ability to prognosticate the clinical course of patients with cancer has historically been
limited to clinical, histopathological, and radiographic features. It has long been clear …

Significant progress has been made in genetic and genomic testing for prostate cancer
across the disease spectrum. Molecular profiling is increasingly relevant for routine clinical …

Purpose: To determine whether metastatic castration–resistant prostate cancers (mCRPC)
partition into molecular phenotypes corresponding to intrinsic differentiation states and …

The androgen receptor (AR) is a master transcription factor that regulates prostate cancer
(PC) development and progression. Inhibition of AR signaling by androgen deprivation is …

Purpose: Although numerous biology-driven subtypes have been described previously in
metastatic castration-resistant prostate cancer (mCRPC), unsupervised molecular subtyping …

Response to androgen receptor signaling inhibitors (ARSI) varies widely in metastatic
castration resistant prostate cancer (mCRPC). To improve treatment guidance, biomarkers …

Resistance to androgen receptor (AR)–targeted therapies for prostate cancer (PCa) is
characteristic of an aggressive subtype called castration-resistant prostate cancer (CRPC) …